NOACs compare favourably to warfarin in new studies

NOACs compare favourably to warfarin in new studies

June 22 2016 Two BMJ studies have further supported the use of alternatives to warfarin for...

Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

May 11 2016 Serious health risks in type 2 diabetes may be reduced more effectively with insulin...

Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

April 27 2016 Methotrexate in combination with sulphasalazine and hydroxychloroquine has been...

SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

April 20 2016 Patients taking sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin,...

Cochrane concludes daily iron supplements improves women’s overall activity

Cochrane concludes daily iron supplements improves women’s overall activity

April 20 2016 A Cochrane review has concluded that daily iron supplementation effectively reduces...

  • NOACs compare favourably to warfarin in new studies

    NOACs compare favourably to warfarin in new studies

    Wednesday, 22 June 2016 14:14
  • Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

    Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

    Wednesday, 11 May 2016 14:15
  • Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

    Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

    Wednesday, 27 April 2016 13:22
  • SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

    SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

    Wednesday, 20 April 2016 13:25
  • Cochrane concludes daily iron supplements improves women’s overall activity

    Cochrane concludes daily iron supplements improves women’s overall activity

    Wednesday, 20 April 2016 13:18

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

diabetes4April 6 2016

An association between the diabetes drug pioglitazone and increased risk of bladder cancer has been identified in a new study. It found no similar risk with rosiglitazone.

The findings published in the British Medical Journal suggest that the risk increases with increasing duration of treatment and higher dose. While the number of patients likely to be affected is small, the effect is significant, so should be taken into consideration when assessing overall risks and benefits of the therapy, the researchers have advised.

Researchers analysed data for over 145,000 patients being treated for diabetes between 2000 and 2013. The data had been supplied by GPs to the UK Clinical Practice Research Datalink. Combined, and the accessed records amounted to nearly 700,000 person years of follow up.

From this, the study identified 622 patients as being newly diagnosed with bladder cancer, equivalent to a crude incidence of 90.2 per 100,000 person years. Pioglitazone was identified with an increased risk of bladder cancer, at 121.0 per 100,000 person years, compared to an average of 88.9 per 100,000 person years where pioglitazone was not used.

It equates to an overall 63% increased risk of incident bladder cancer, said the researchers. Rosiglitazone had a similar level of risk to non exposure at 86.2 compared to 88.9 per 100,000 person years.

The difference between the two glitazone drugs suggest the difference “is drug specific and not a class effect,” they concluded. Both pioglitazone and rosiglitazone entered the UK market in 2000 and were intended for the same target population. “Given their similarities, it is unlikely that confounding by indication or detection bias can explain the association observed with pioglitazone.

“Of note, although the biological mechanism for pioglitazone induced bladder cancer is not clear, this imbalance in the risk of bladder cancer between these two thiazolidinediones could likely be explained by pharmacological differences.”

The researchers point out that pioglitzaone has dual activity on the peroxisome proliferator activated receptors (PPAR) α and γ, while rosiglitazone is only active at PPAR γ.
“Although differences in PPAR activity are possible explanations for the observed association, additional studies are needed to better understand the biological mechanism behind the possible pioglitazone specific effect on the bladder.”

A second study, also published in the same issue of the BMJ has looked at diabetes medicines, particularly gliptins and glitazones, and the relationship to the risks of amputation, blindness, severe kidney failure, hyperglycaemia and hypoclycaemia.

This time the researchers assessed data from the QResearch database used in 1,243 GP practices in England, and covering almost 470,000 adults with type 2 diabetes between 2007 and 2015. The analysis found that 21,308 (4.5%) patients received prescriptions for glitazones and 32,533 (6.9%) received prescriptions for gliptins. It also looked at whether the drugs were given as monotherapy or in combination.

Findings included:

  • there were significantly lower risks of hyperglycaemia among patients prescribed dual therapy involving metformin with either gliptins or glitazones compared with metformin monotherapy;
  • triple therapy with metformin, sulphonylureas, and either gliptins or glitazones was associated with significantly higher risks of hypoglycaemia than those prescribed metformin monotherapy, but these risks were similar to those involving dual therapy with metformin and sulphonylureas;
  • triple therapy with metformin, sulphonylureas, and glitazones was associated with a significantly reduced risk of blindness compared with metformin monotherapy.

Commenting on both studies, the BMJ said: “Both studies are observational so no firm conclusions can be drawn about cause and effect. However, the researchers say these results may have implications for prescribing, and suggest doctors and patients should be aware when assessing the overall risks and benefits of diabetes drugs.”

Links:

BMJ announcement

M Tuccori et al. ‘Pioglitazone use and risk of bladder cancer: population based cohort study’. BMJ 2016; 352: i1541

J Hippisley-Cox and C Coupland. ‘Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care’. BMJ 2016; 352: i1450

Clinical News

June 29 2016 The NHS should support clinical pharmacist roles in community pharmacies as well as at GP practices, the New NHS Alliance has proposed.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...